Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers

Nicotine and Tobacco Research

Volumn 17, Issue 1, 2015, Pages 106-113

  Ravva, Patanjali ^a   Gastonguay, Marc R ^b   Faessel, Hélène M ^c   Lee, Theodore C ^d   Niaura, Raymond ^e  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Metrum Research Group LLC   (United States)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^d PFIZER INC   (United States)

^e Schroeder Institute for Tobacco Research and Policy Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; PLACEBO; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ADULT; ARTICLE; ASSOCIATION; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINNESOTA NICOTINE WITHDRAWAL SCALE; MONTE CARLO METHOD; PHARMACODYNAMICS; PHARMACOKINETICS; PLACEBO EFFECT; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SINGLE DRUG DOSE; SMOKING; SMOKING CESSATION; SMOKING URGE SCALE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DRUG THERAPY; MIDDLE AGED; PROCEDURES;

ADOLESCENT; ADULT; BENZAZEPINES; CRAVING; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; QUESTIONNAIRES; QUINOXALINES; SMOKING; SMOKING CESSATION;

EID: 84922461879     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntu154     Document Type: Article

References (36)

1. Piasecki TM. Relapse to smoking. Clin Psychol Rev. 2006;26:196-215.
2. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Smoking withdrawal dynamics: I. abstinence distress in lapsers and abstainers. J Abnorm Psychol. 2003;112:3-13.
3. Piasecki TM, Niaura R, Shadel WG, Abrams D, Goldstein M, Fiore MC, Baker TB. Smoking withdrawal dynamics in unaided quitters. J Abnorm Psychol. 2000;109:74-86.
4. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the a4ß2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985-994.
5. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha-4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007;28:316-325.
6. Rollema H, Shrikhande A, Ward KM, et al. Preclinical properties of the alpha4beta2 nAChR partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Neuropsychopharmacology. 2009;160:334-345.
7. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007;32:912-923.
8. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an a4ß2 nicotinic acetylcholine partial receptor agonist, vs. sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA. 2006;296:47-55.
9. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571-1577.
10. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology. 2008;197:371-377.
11. Brandon TH, Drobes DJ, Unrod M, et al. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology. 2011;218:391-403.
12. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009;65:144-149.
13. Perkins KA, Mercincavage M, Fonte CA, Lerman C. Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology. 2010;210:45-51.
14. Hitsman B, Hogarth L, Tseng L-J, et al. Dissociable effect of acute varenicline on tonic versus cue-provoked craving in non-treatment-motivated heavy smokers. Drug Alcohol Depend. 2013;130:135-141.
15. Bonate PL. Recommended reading in population pharmacokinetic pharmacodynamics. AAPS J. 2005;7:E363-373.
16. Duffull SB, Wright DF, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses-a clinical viewpoint. Br J Clin Pharmacol. 2011;71:807-814.
17. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry-Population pharmacokinetics. Washington, DC: US Department of Health and Human Services; 1999.
18. Wright DF, Winter HR, Duffull SB. Understanding the time course of pharmacological effect: a PKPD approach. Br J Clin Pharmacol. 2011;71:815-823.
19. Gibaldi M, Perrier D. Physiological pharmacokinetic models. 2nd ed. Pharmacokinetics. New York, NY: Marcel Dekker Inc;1982: 355-384.
20. Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm. 1985;13:185-201.
21. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol. 1992;32:185-209.
22. Gomeni R, Teneggi V, Iavarone L, Squassante L, Bye A. Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling. Pharm Res. 2001;18:537-543.
23. Shiffman SM, Jarvik ME. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology. 1976;50:35-39.
24. Shiffman SM, Shadel WG, Niaura R, et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology. 2003;166:343-350.
25. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale. Curr Med Res Opin. 2005;21:749-760.
26. Niaura R, Sayette M, Shiffman S, et al. Comparative efficacy of rapidrelease nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction. 2005;100:1720-1730.
27. Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol. 2006;46:1439-1448.
28. Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol. 2006;46:991-998.
29. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User's Guides. Ellicott City, MD: Icon Development Solutions; 2009.
30. Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol. 2009;68:669-681.
31. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res. 1995;12:1845-1855.
32. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
33. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28:171-192.
34. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-528.
35. Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein, AH. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet. 2010;49:799-816.
36. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine partial receptor agonist, vs. placebo or sustainedrelease bupropion for smoking cessation. A randomized controlled trial. JAMA. 2006;296:56-63.